Last reviewed · How we verify
Prourokinase
At a glance
| Generic name | Prourokinase |
|---|---|
| Also known as | Reocmbinant Human Prourokinase for Injection, TIANJIN TASLY PHARMACEUTICAL CO.,LTD |
| Sponsor | Suzhou Landing Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) (PHASE3)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer (PHASE3)
- Intravenous Thrombolysis and NOAC (PHASE3)
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months (PHASE3)
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) (PHASE3)
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PHASE3)
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prourokinase CI brief — competitive landscape report
- Prourokinase updates RSS · CI watch RSS
- Suzhou Landing Pharmaceuticals portfolio CI